on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Progresses with Semaglutide ODF Program
BioNxt Solutions Inc., a bioscience innovator, has announced updates on its semaglutide oral thin-film (ODF) initiative. The project is in its early stages, focusing on semaglutide as part of a broader GLP-1 receptor agonist platform strategy. Semaglutide is widely used for type 2 diabetes and obesity treatment, and BioNxt aims to explore its feasibility as a model for the sublingual delivery of peptide therapeutics.
BioNxt's strategy extends beyond individual products, seeking to develop a scalable ODF platform for GLP-1 receptor agonists and peptide drugs. The goal is to enhance delivery systems for known compounds like tirzepatide and liraglutide. This approach could potentially generate new intellectual property in formulation and delivery systems.
The global GLP-1 market is expanding rapidly, driven by rising obesity and diabetes prevalence. BioNxt aims to introduce patient-friendly delivery formats, enhancing convenience over injectables and positioning itself for potential market advancement.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news